TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18585494
Drug: Full prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full prescription drug coverage (no copays, coinsurance, or deductibles) for statins, beta-blockers, ACE inhibitors, and angiotensin II receptor blockers.
Study: 18585494
Drug: Full prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full prescription drug coverage (no copays, coinsurance, or deductibles).
Study: 2884879
Drug: SMS 201-995
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMS 201-995 (25 micrograms, subcutaneously, twice daily)
Study: 25194408
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplementation (250 mg, three times per week for 8 weeks)
Study: 1772457
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection (saline)
Study: 18082217
Drug: Prostataplex soft
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostataplex soft gels (2 soft gels daily for 12 weeks)
Study: 18082217
Drug: Placebo soft
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo soft gels (2 soft gels daily for 12 weeks)
Study: 11037850
Drug: Oral cloxacillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cloxacillin and cefixime
Study: 8610379
Drug: BT563 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: BT563 (10 mg/day for 12 days)
Study: 8610379
Drug: ATG (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATG (5 mg/kg/day for 7 days)
Study: 8240460
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 2 mg E2
Study: 8240460
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 4 mg E2
Study: 8240460
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 8 mg E2
Study: 8240460
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 0.3 mg E2
Study: 8240460
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of E2 (overall)
Study: 3486756
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose (SD) of 2 mg/kg intravenously
Study: 3486756
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose (SD) of 2 mg/kg plus a 2 mg/kg/h intravenous infusion (SDI)
Study: 24434128
Drug: Pulsatile Electrostatic
Normalized name: PULSATILLA PRATENSIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsatile Electrostatic Field (PESF) treatment in group C (T2DM with leg ulcers)
Study: 24434128
Drug: Pulsatile Electrostatic
Normalized name: PULSATILLA PRATENSIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsatile Electrostatic Field (PESF) treatment in group A (obese without glucose intolerance)
Study: 24434128
Drug: Pulsatile Electrostatic
Normalized name: PULSATILLA PRATENSIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsatile Electrostatic Field (PESF) treatment in group B (obese intolerant to glucose)
Study: 8636011
Drug: Paclitaxel 240
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 240 mg/m2
Study: 8636011
Drug: Paclitaxel 270
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 270 mg/m2
Study: 8636011
Drug: Paclitaxel 3-h
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 3-h infusion
Study: 381955
Drug: Ticrynafen, 125‐‐250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticrynafen, 125‐‐250 mg/day
Study: 381955
Drug: Probenecid, 0.5‐‐1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probenecid, 0.5‐‐1.0 g/day
Study: 25033745
Drug: Warmed irrigation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warmed irrigation solutions (37 °C) in group W
Study: 25033745
Drug: Room temperature
Normalized name: ROOM DEODORIZER POWDER MENTOR #3202
Approvals — FDA: no, EMA: no, PMDA: no
Description: Room temperature irrigation solutions (21 °C) in group R
Study: 21964530
Drug: COX-2 or
Normalized name: Inova 8-2 Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: COX-2 or 5-LOX inhibitors plus chemotherapy
Study: 8655160
Drug: Azithromycin Regimen
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin Regimen A - 1.0 g once weekly for 4 weeks
Study: 8655160
Drug: Azithromycin Regimen
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin Regimen B - 500 mg daily for 7 days
Study: 1513195
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion (mean total dose 6.4 +/- 2.7 mg/kg)
Study: 18476293
Drug: Drug Conservation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug Conservation (DC)
Study: 16571140
Drug: Recombinant Hepatitis
Normalized name: Recombinant hepatitis B human immunoglobulin
DrugBank: Lenvervimab (DB17814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant Hepatitis B virus vaccine (40 microg for HIV positive patients, 20 microg for controls)
Study: 8624183
Drug: 8 mg/d
Normalized name: Neupro 8 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg/d of buprenorphine
Study: 8624183
Drug: 30 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/d of methadone
Study: 8624183
Drug: 80 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/d of methadone
Study: 8624183
Drug: low-dose methadone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: low-dose methadone
Study: 8624183
Drug: high-dose methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: high-dose methadone
Study: 2578493
Drug: Oral hydroxyzine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hydroxyzine, 25 mg four times a day
Study: 29663828
Drug: Nurse-led palliative
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-led palliative care intervention integrated with anti-retroviral therapy (ART)
Study: 24656538
Drug: Cangrelor infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cangrelor infusion (bolus plus 2-h infusion) and ticagrelor (180 mg) at 0.5 h (n = 6) or 1.25 h (n = 6)
Study: 24656538
Drug: Ticagrelor (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (90 mg twice daily for either 6 doses or 7 doses)
Study: 24656538
Drug: Ticagrelor given
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor given before or during infusion of cangrelor
Study: 24656538
Drug: Ticagrelor during
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor during infusion of cangrelor
Study: 10817002
Drug: Unilateral spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral spinal anesthesia with 8 mg of 0.5% hyperbaric bupivacaine
Study: 10817002
Drug: Combined sciatic-femoral
Normalized name: Sus scrofa temporal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined sciatic-femoral nerve block with 25 ml of 2% mepivacaine
Study: 6841658
Drug: Deltoid morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deltoid morphine (8 and 16 mg)
Study: 6841658
Drug: Deltoid methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deltoid methadone (10 mg)
Study: 29152781
Drug: Glecaprevir and
Normalized name: glecaprevir and pibrentasvir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glecaprevir and pibrentasvir (G/P; 300 mg/120 mg) for 12 weeks
Study: 29152781
Drug: Glecaprevir and
Normalized name: glecaprevir and pibrentasvir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glecaprevir and pibrentasvir (G/P; 300 mg/120 mg) for 16 weeks
Study: 27819111
Drug: Loop diuretics
Normalized name: LOOP DIURETICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loop diuretics (including doses ≥80 mg furosemide equivalent/day)
Study: 27819111
Drug: No loop
Approvals — FDA: no, EMA: no, PMDA: no
Description: No loop diuretics
Study: 24388010
Drug: 500 index
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 index of reactivity (IR) tablets
Study: 24388010
Drug: 300 index
Normalized name: gr pol-orc/sw ver/rye/Kent/tim 300 index of reactivity SUBLINGUAL TABLET, SUBLINGUAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 index of reactivity (IR) tablets
Study: 22475306
Drug: Control (benzocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (benzocaine gel)
Study: 21992993
Drug: 0.5% timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% timolol aqueous solution
Study: 10465182
Drug: Transdermal oestradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal oestradiol 80 microg with continuous oral norethisterone 1 mg
Study: 373393
Drug: Potassium chloride
Normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Potassium chloride (1500 mg daily)
Study: 2565210
Drug: Amiloride (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride (5 mg daily)
Study: 373393
Drug: Triamterene (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triamterene (75 mg daily)
Study: 24795252
Drug: Hydrochlorothiazide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (50 mg daily)
Study: 21861935
Drug: Hylan G-F
Normalized name: hylan G-F 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hylan G-F 20 injections (4 courses of 3 × 2.0 ml at 6 month intervals)
Study: 21861935
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care for knee OA without injections
Study: 19718004
Drug: Periodontal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periodontal therapy combined with tacrolimus
Study: 24593836
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene instructions only (Control)
Study: 17230289
Drug: 50 IU
Normalized name: Pegaspargase 750 IU/1 ML Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 IU Syntocinon (in 30 ml N saline)
Study: 17230289
Drug: 800 mcg
Normalized name: Biotin 800 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mcg misoprostol (in 30 ml N saline)
Study: 17230289
Drug: 30 ml
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml N saline (control)
Study: 7821456
Drug: Oral tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tetracycline (250 mg twice daily for 12 weeks)
Study: 7821456
Drug: Oral tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tetracycline (250 mg twice daily for 12 weeks) and topical prednisolone (for the first 7 days)
Study: 7821456
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (Control group A)
Study: 2839579
Drug: Intranasal sprays
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal sprays of recombinant beta serine interferon (rIFN‐beta ser)
Study: 2839579
Drug: Daily nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily nasal drops of rIFN‐beta ser
Study: 2839579
Drug: Low-dose rIFN‐beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose rIFN‐beta ser
Study: 2839579
Drug: High-dose rIFN‐beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose rIFN‐beta ser
Study: 18200775
Drug: Nifedipine (twice-daily)
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine (twice-daily)
Study: 14741066
Drug: Extended-release lovastatin
Normalized name: lovastatin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release lovastatin (20 mg)
Study: 14741066
Drug: Immediate-release lovastatin
Normalized name: lovastatin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release lovastatin (20 mg)
Study: 11716446
Drug: Oral cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclophosphamide 50 mg/day and tamoxifen 20 mg/day plus 1‐hexylcarbamoyl‐5‐fluorouracil 300 mg/day for 2 years
Study: 11716446
Drug: Oral cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclophosphamide 50 mg/day and tamoxifen 20 mg/day for 2 years
Study: 26626823
Drug: Normal energy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal energy food foam (NEF1, 280 kJ/400 mL)
Study: 26626823
Drug: Very low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low energy food foam (VLEF, 36 kJ/400 mL)
Study: 23136318
Drug: GEL (lubricant
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEL (lubricant gel use before speculum insertion)
Study: 23136318
Drug: NO GEL
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NO GEL (no lubricant gel use before speculum insertion)
Study: 23136318
Drug: GEL (lubricant
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEL (lubricant gel use) in premenopausal women
Study: 23136318
Drug: GEL (lubricant
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEL (lubricant gel use) in postmenopausal women
Study: 23136318
Drug: GEL (lubricant
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEL (lubricant gel use) in women of reproductive age
Study: 20032194
Drug: Vabicaserin (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vabicaserin (oral administration)
Study: 20032194
Drug: Vabicaserin metabolism
Normalized name: Vabicaserin
DrugBank: Vabicaserin (DB12071)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vabicaserin metabolism
Study: 15750171
Drug: Multiple-time graphical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-time graphical analysis of 18F-fluoro-L-DOPA uptake constant (K(i), min(−1)) in basal ganglia
Study: 15750171
Drug: SPM analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPM analysis of 18F-fluoro-L-DOPA uptake constant (K(i), min(−1)) in basal ganglia
Study: 9147856
Drug: Clodronate 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate 3 x 800 mg orally
Study: 1491771
Drug: Cyclic hormone
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic hormone replacement therapy with conjugated estrogens (0.625 mg and 1.25 mg) and progestagens (medroxyprogesterone acetate or medrogestone)
Study: 22520669
Drug: 3-monthly GP
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 3-monthly GP visits (intensive care)
Study: 20479407
Drug: Paclitaxel added
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel added to adjuvant doxorubicin plus cyclophosphamide (AC) chemotherapy
Study: 20479407
Drug: AC chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC chemotherapy alone
Study: 10926637
Drug: 7 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 g/day of pyruvate
Study: 8874117
Drug: Volume expansion
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume expansion with 9 ml of 3 ml albumin, 3 ml glucose, and 3 mEq of sodium bicarbonate (group B, n = 24)
Study: 8874117
Drug: Volume expansion
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume expansion with 4.5 ml albumin and 4.5 ml glucose (group C, n = 14)
Study: 31581591
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein supplement enriched with leucine
Study: 22385885
Drug: 10mg fluvastatin/20mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg fluvastatin/20mg valsartan daily for 30 days
Study: 3394886
Drug: Imipramine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine treatment for 6 weeks
Study: 16826400
Drug: Psilocybin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin (30 mg/70 kg)
Study: 16826400
Drug: Methylphenidate hydrochloride
Normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate hydrochloride (40 mg/70 kg)
Study: 14655885
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave therapy (ESWT) - 3 sessions of 3000 shock waves/session at 0.2 mJ/mm2, weekly intervals
Study: 14655885
Drug: Conventional conservative
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional conservative treatment (iontophoresis with diclofenac and oral NSAID) for 12 weeks followed by ESWT protocol
Study: 11035668
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 2,000 microg via metered‐dose inhaler for 5 consecutive days
Study: 30203681
Drug: Contraceptive vaginal
Normalized name: VCF 4% Contraceptive Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contraceptive vaginal rings with 300 µg 17β-estradiol and 75-125 µg/day of etonogestrel (ENG)
Study: 30203681
Drug: Contraceptive vaginal
Normalized name: VCF 4% Contraceptive Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contraceptive vaginal rings with 300 µg 17β-estradiol and 500-900 µg/day of nomegestrol acetate (NOMAC)
Study: 30203681
Drug: ENG-E2 125/300
Approvals — FDA: no, EMA: no, PMDA: no
Description: ENG-E2 125/300 µg/day group
Study: 30203681
Drug: NuvaRing (ENG/ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: NuvaRing (ENG/ethinylestradiol 120/15 µg)
Study: 24874006
Drug: Web‐based Solution‐Focused
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web‐based Solution‐Focused Brief Therapy (SFBT) intervention (n=131)
Study: 23327035
Drug: Dexmedetomidine (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (Group D) - loading dose of 1 microg/kg IV over ten minutes, followed by continuous infusion at 0.5 microg/kg/hr throughout surgery
Study: 23327035
Drug: Saline (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (Group S) - same volume as dexmedetomidine infusion
Study: 20573787
Drug: 35 micro
Normalized name: Ethinyl estradiol 35 microgram and norethindrone 1 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 micro g Se as l-selenomethionine
Study: 20573787
Drug: 21 micro
Normalized name: Ipratropium bromide 21 microgram/actuation nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21 micro g Se as l-selenomethionine
Study: 20573787
Drug: 0 micro
Normalized name: EM 2400 Micro Volume
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 micro g Se (placebo)
Study: 18043579
Drug: Dose-intensive epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-intensive epirubicin and cyclophosphamide with filgrastim and progenitor cell support (DI-EC)
Study: 18043579
Drug: Standard-dose anthracycline-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose anthracycline-based chemotherapy (SD-CT)
Study: 18506618
Drug: Integrated Assertive
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated Assertive Community Treatment (IACT)
Study: 16897413
Drug: Assertive Community
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assertive Community Treatment only (ACTO)
Study: 12827120
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream with heat for 20 minutes
Study: 12827120
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream for 60 minutes without heat
Study: 1893291
Drug: Synthetic human
Normalized name: Synthetic human secretin
DrugBank: Secretin human (DB09532)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synthetic human calcitonin 0.25 mg
Study: 1893291
Drug: Synthetic human
Normalized name: Synthetic human secretin
DrugBank: Secretin human (DB09532)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synthetic human calcitonin 0.125 mg
Study: 6380896
Drug: Nitrogen mustard
Normalized name: Nitrogen mustard
DrugBank: Mechlorethamine (DB00888)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitrogen mustard (0.1 mg/kg body weight) administered in 3 intravenous bolus injections over 3-5 weeks
Study: 21993365
Drug: Medication Event
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Medication Event Monitoring System (MEMS) and pill count
Study: 21993365
Drug: Pill count
Normalized name: Pill Counting Tray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill count alone (control group)
Study: 20859153
Drug: Continuous wound
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous wound infusion below the fascia using ropivacaine and ketoprofene
Study: 20859153
Drug: Continuous wound
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous wound infusion above the fascia using ropivacaine and ketoprofene
Study: 16160802
Drug: Strict metabolic
Normalized name: Euphrasia stricta extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strict metabolic control with insulin administration (fasting glucose levels to 90 mg/dl and 130 mg/dl postprandially)
Study: 9002334
Drug: Mega-dose capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mega-dose capsule distribution (100,000 IU for 6-12 months; 200,000 IU for 1-5 years)
Study: 1618248
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of quinine (500 mg)
Study: 1618248
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of quinine (500 mg)
Study: 1618248
Drug: Both oral
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both oral and intravenous administration of quinine (500 mg)
Study: 6204486
Drug: Topical clobetasol-17-propionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical clobetasol-17-propionate
Study: 31227432
Drug: Abiraterone (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abiraterone (1000 mg daily) + Dasatinib (100 mg daily)